Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Moderna, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Lonza Group AG / Key word (s): Annual Results/Sustainability Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports 03-Apr-2025 / 07:00 CET/CEST ...

Annual Results/Sustainability Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports 03-Apr-2025 / 07:00 CET/CEST Release ...

Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low following news that the Food and ...

Shares in Moderna and Novavax fell Monday, following a Wall Street Journal report that the Food and Drug Administration’s top vaccine official has been pushed out. Shares in some larger drugmakers, ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway ...

The Trump administration’s decision to cut funding for Gavi, as part of a broader reduction in foreign aid, may have ...